Coverage / AUTL / Trade Card

AUTL

Autolus Therapeutics PLC

OPPORTUNISTIC BUY 2026-08-09 Data 34 days old USD 2.11 Healthcare - BiotechnologyAWAIT ENTRY
ACTIONABLEMethodology gates passed
56

Position levels

Currenttoday
USD 2.11
Buy <=wait / entry
USD 1.67
Trim >=take some off
USD 2.40
Thesis breakA confirmed AUCATZYL revenue miss below the 2026 guidance range combined with a ...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case23%100 / 10023.0
Base case49%62 / 10030.4
Bear case28%10 / 1002.8
Weighted conviction56 / 100 - OPPORTUNISTIC BUY

Top risks

  • BioNTech strategic CAR-T collaboration including $200M investment, manufacturing access rights, and co-commercialization options for obe-cel and other programs
  • Reiterated 2026 AUCATZYL net revenue guidance of $120 - $135 million with expected shift to positive gross margin
  • Operational efficiency initiative with ~13% workforce reduction, ~$15M annualized opex savings from 2027, and doubled manufacturing capacity
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.